Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/10/2009 First Published: 4/1/2002


1.		Phase III Randomized Study of Cyclophosphamide and Prednisone With or Without Immune Globulin in Pediatric Patients With Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				8 and under				NCI				COG-ANBL00P3 ANBL00P3, NCT00033293

Last Modified: 1/23/2008 First Published: 10/17/2007


2.		Phase I/II Pilot Study of Intravenous Human Immune Globulin Intravenous in Patients With Cardiac-Associated Primary Amyloidosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Adult				Other				BRCC-BHS-06127 UTCI-2645, 2645, NCT0054736


3.		IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				GCan-01 NCT00294476

First Published: 12/9/2008


4.		Phase II Study of Conditioning Comprising Fludarabine Phosphate, Busulphan, and Anti-Lymphocyte Globulin Followed by HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation From Filgrastim (G-CSF)-Mobilized Related Donor in Older Patients With Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				56 to 74				Other				IPC-2005-004 IPC 2005-004, EUDRACT-2005-005051-17, IPC-T2A, INCA-RECF0452, NCT00806767

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute